Business Wire - September 11, 2009

MINNEAPOLIS - E-18 Corp. (OTCBB:ETEN), through its wholly owned subsidiary, SquareOne Medical, Inc., doing business as Protectus Medical Devices ("Protectus Medical Devices"), today announces the release of a SmallcapInsights.com article by industry veteran, Dr. John Faessel.

Entitled "UPDATE: A Truly Unique 'Safe Needle,'" Dr. Faessel guides readers through the enormous opportunity for the Protectus Safety Syringe as the sole safety syringe that automatically self-sheaths. This update delves into the tolls the healthcare system faces due to accidental needlesticks, as well as the international opportunities for the Protectus Safety Syringe based on the Company's recent international patent-pending status.

From the article:

"Needle penetrations can lead to the transmission of more than 20 bloodborne viruses, including HIV, hepatitis B and hepatitis C, from the source person to the healthcare worker. An estimated 600,000 to 1 million reported accidental injuries from conventional needles and sharps occur annually in the United States."

Dr. Faessel goes on to say, "On 8-27-2009 ETEN announced the completion of an international patent filing for its revolutionary self-sheathing medical safety syringe technology. With over 30 billion syringes used annually around the world, including an estimated 8 billion units in the U.S. alone, the market for a truly safe syringe is indeed staggering. This international patent now paves the way for even greater opportunities abroad."

A link to this article is available on the SmallcapInsights.com website: http://www.smallcapinsights.com.

The Protectus Medical Safety Syringe is designed to significantly reduce or eliminate accidental needlestick injuries that have plagued the healthcare workplace for decades. More information about Protectus Medical Devices may be found at the Company's corporate website at www.protectusmedical.com.

About E-18 Corp.

E-18 Corp., through its wholly owned subsidiary, SquareOne Medical, Inc., doing business as Protectus Medical Devices, develops and markets innovative safety medical percutaneous devices that, collectively, have the potential to dramatically reduce needlestick injuries for medical professionals worldwide. In the nearly $5 billion global hypodermic syringe market, the Protectus Safety Syringe, the Company's lead product, is the only fully automatic, self-sheathing hypodermic safety syringe that currently meets the functional definition of "Self-Sheathing" mandated by the U.S. Federal Government. None of the manufacturers of other devices on the market can make this claim. Protectus Medical Devices has successfully patented its automatic, self-sheathing hypodermic safety syringe product, and, based on the results of full comparison clinical trials, the Protectus Safety Syringe (formerly the SquareOne Safety Syringe) has received the required 510(k) permission from the U.S. FDA to manufacture and market the device in the U.S. More information about the Company may be found at www.protectusmedical.com.

Forward-Looking Statements

Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties. Words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import also identify forward-looking statements. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of E-18 Corp. can be found in the filings of E-18 Corp. with the U.S. Securities and Exchange Commission.

SEC Section 17(b) Disclosure: SmallcapInsights.com is a wholly owned subsidiary of Trilogy Capital Partners, Inc. ("Trilogy"). Trilogy has been engaged by E-18 Corp. ("ETEN") to provide investor relations services for compensation including a monthly retainer of $10,000 for an initial twelve month term and 450,000 shares of restricted common stock of ETEN, to be distributed in equal monthly installments over a six month period.

Contacts

Company Contact:

E-18 Corp.

John Salstrom, President and CEO

1-800-778-8438

moreinfo@protectusmedical.com

or

Financial Communications Contact:

Trilogy Capital Partners

Darren Minton, Vice President

Toll-free: 800-592-6067

info@trilogy-capital.com
090911
BW090921

Copyright © 2009 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .